Monday, January 22, 2007
Dallas-based Access Pharmaceuticals receives chemotherapy patent
Company's oral rinse will be used to fight mouth ulcers.
DALLAS — Access Pharmaceuticals Inc. said Monday that it has been approved for a patent to make a product used to manage oral mucositis, a side-effect from radiation and chemotherapy.
The company also received marketing clearance in December from the Food and Drug Administration for its product, MuGard.
MuGard is an oral rinse product used for the prevention and treatment of oral mucositis, or painful ulcers in the mouth. The market for oral mucositis is estimated to exceed $1 billion world-wide, said Access Pharmaceuticals. The company estimates that up to 40 percent of cancer patients undergoing radiation and chemotherapy are affected by oral mucositis.
Source: Access Pharmaceuticals Inc.
Email
|
Print
|
0 Comments
|
Contribute
|
-
»Dallas County to launch new prescription drug savings program
-
»Dallas jury returns $1.9 million verdict against Carrollton-based nutritional supplement provider AdvoCare
-
»Coppell-based Mannatech expanding to four additional European countries
-
»Dallas-based ACS acquires Pharm/DUR
-
»Coppell-based Mannatech reaches settlement with Texas Attorney General over deceptive trade practices
|
an event
|
a restaurant
|
|
a garage sale
|
a drink special
|
|
a movie showtime
|
local music
|
a job
|
a house
|
|
a deal
|
a pet
|
